{"id":"dinutuximab-immunotherapy","safety":{"commonSideEffects":[{"rate":"34%","effect":"Fatigue"},{"rate":"28%","effect":"Nausea"},{"rate":"24%","effect":"Vomiting"},{"rate":"21%","effect":"Diarrhea"},{"rate":"19%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Dinutuximab is a chimeric monoclonal antibody that targets the disialoganglioside GD2, a glycosphingolipid present on the surface of neuroblastoma cells.","oneSentence":"Monoclonal antibody targeting GD2","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:33:03.506Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroblastoma"}]},"trialDetails":[{"nctId":"NCT06450041","phase":"PHASE2","title":"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial","status":"RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2024-12-16","conditions":"Neuroblastoma","enrollment":62},{"nctId":"NCT02573896","phase":"PHASE1","title":"Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2019-01-14","conditions":"Neuroblastoma","enrollment":13},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT02559778","phase":"PHASE2","title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2015-09","conditions":"Neuroblastoma","enrollment":500},{"nctId":"NCT04751383","phase":"PHASE1","title":"Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma","enrollment":12},{"nctId":"NCT05754684","phase":"PHASE2","title":"Quadruple Immunotherapy for Neuroblastoma","status":"RECRUITING","sponsor":"Hong Kong Children's Hospital","startDate":"2022-01-01","conditions":"Neuroblastoma Recurrent","enrollment":29},{"nctId":"NCT06485947","phase":"PHASE1","title":"Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2025-01-28","conditions":"Neuroblastoma","enrollment":38},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT02169609","phase":"PHASE2","title":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2014-11-26","conditions":"Neuroblastoma, Neoplasm, Residual, Effects of Immunotherapy","enrollment":24},{"nctId":"NCT02641782","phase":"PHASE2","title":"NB2013-HR German (GPOH) / Dutch (DCOG) Trial","status":"TERMINATED","sponsor":"University of Cologne","startDate":"2015-11","conditions":"Neuroblastoma","enrollment":3},{"nctId":"NCT05272371","phase":"PHASE1","title":"Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease","status":"RECRUITING","sponsor":"Jagiellonian University","startDate":"2021-12-01","conditions":"High-Risk Neuroblastoma","enrollment":20},{"nctId":"NCT01704716","phase":"PHASE3","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2002-02","conditions":"Neuroblastoma","enrollment":3300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":159,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ch14.18","Sargramostim","GM-CSF","Isotretinoin","13-cis-retinoic acid, or RA"],"phase":"phase_2","status":"active","brandName":"Dinutuximab. Immunotherapy","genericName":"Dinutuximab. Immunotherapy","companyName":"Fundació Sant Joan de Déu","companyId":"fundaci-sant-joan-de-d-u","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Monoclonal antibody targeting GD2 Used for Neuroblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}